- Price
- $13.11
- Day
- +13.11%
- Mkt Cap
- $185.69M
- 52W Range
- $10.47 – $33.20
- Volume
- 876.8K
- Beta
- 0.96
Find a company by name or ticker and open its page
Breaking news, press releases, and analyst updates.
Most recent articles and analysis covering this company.
PALO ALTO, Calif., & NEW YORK--(BUSINESS WIRE)--Evommune, Inc. (NYSE: EVMN) (the “Company” or “Evommune”), a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, today announced the first patient was dosed in its Phase 2b clinical trial evaluating a potent, highly selective oral small molecule antagonist of MRGPRX2, EVO756, for the prophylactic treatment of migraine. "Initiating this migraine trial is an exciting mileston.
Read full article